Roobcio / Shutterstock.com
AstraZeneca has predicted a dip in revenue this year after it loses patent exclusivity on its anti-cholesterol drug Crestor (rosuvastatin calcium).
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
AstraZeneca, patents, revenue, Crestor, Pascal Soriot